BrainStorm Cell Therapeutics, a prominent developer of adult stem cell therapeutics for neurodegenerative diseases, issued an update on the recent grant and allowance of three patent applications related to NurOwn® and NurOwn-Exosomes. The European Patent Office approved patent No. 3105587, titled 'Method of Qualifying of Cells,' which outlines a method for determining the suitability of a cell population for ALS treatment. This patent also covers claims for an isolated population of mesenchymal stem cells designed for ALS treatment.

Furthermore, the Australian Patent Office granted patent No. 2019252987, titled 'Cell-Type Specific Exosomes and Use Thereof,' which involves an isolated Exosomes population derived from MSC-NTF cells and a pharmaceutical composition for neurodegenerative diseases.

The acquisition of the European patent is a crucial step in safeguarding BrainStorm's proprietary NurOwn technology, especially concerning ALS treatment. The Australian patent is a significant accomplishment, representing the first grant for specialized MSC-NTF cell exosomes and highlighting the evolution of BrainStorm's exosome technology. With existing patents in the US, Canada, Israel, Brazil, and Japan, securing the European patent strengthens BrainStorm's global position for potential commercial partnerships, thereby expanding the reach and impact of NurOwn.

Source: prnewswire.com